Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Spinal Cord Injuries, Type 2 Diabetes
Phase PHASE4
Enrollment 50
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.

Design

Study type: Interventional Phases: Phase4 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Semaglutide Injectable Product — A GLP-1 inhibitor used to control T2DM
  • Other: Placebo — Saline solution will be administered with the same frequency as semaglutide and participants will be instructed how to use the saline in the same manner as the active drug group.

Primary Outcomes

  • Glucose tolerance (Baseline to 24 weeks)
  • Insulin action (Baseline to 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-04-11
Completion: 2029-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Marzieh Salehi
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Marzieh Salehi, MD (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center at San Antonio
Contact Information
Study Contact:
Marzieh Salehi, MD
210-567-6691
salehi@uthscsa.edu
Andrea Hansis-Diarte, MPh
210 567 3208
hansisdiarte@uthscsa.edu
Matthew A Davis
davism13@uthscsa.edu
University Health - Texas Diabetic Institute
Interventions
  • Drug: Semaglutide Injectable Product — A GLP-1 inhibitor used to control T2DM
  • Other: Placebo — Saline solution will be administered with the same frequency as semaglutide and participants will be instructed how to use the saline in the same manner as the active drug group.
Study Locations (2 sites)
University Health - Texas Diabetic Institute, San Antonio, Texas 78207 United States
University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229 United States
Eligibility Criteria
Inclusion Criteria: 1. Male and female subjects aged 18-70 years (inclusive) at screening 2. More than one year after spinal cord injury 3. Levels if injury C2-L2 with Asia Impairment Scale A, B, C or D. 4. Provision of signed and dated written informed consent prior to any study specific procedures 5. Diagnosed with T2DM with glucose control managed with diet and metformin monotherapy where no significant dose changes (increase or decrease ≥ 50%) have occurred in the three months prior to screening 6. HbA1c 6.0-9.0% at screening 7. BMI \> 22 kg/m2 at screening 8. Female subjects of childbearing potential must have a negative pregnancy test at screening and randomization, and must not be lactating 9. Females of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from screening and must agree to continue using such precautions through to the end of the study. It is strongly recommended for the male partner of a female subject to also use male condom plus spermicide throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Exclusion Criteria: 1. History of, or any existing condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product, put the subject at risk, influence the subject's ability to participate or affect the interpretation of the results of the study and/or any subject unable or unwilling to follow study procedures. 2. Any subject who has received another investigational product as part of a clinical study within the last 30 days or 5 half-lives of the drug (whichever is longer) at the time of screening 3. Taking mirabegron or other glucose altering medications 4. Taking steroids within the past 1 year 5. Significant anemia (hemoglobin\<11g/dL) 6. History of gastric outlet obstruction or chronic diarrhea 7. History of a chronic neurological illness other than SCI (i.e.; MS, etc) 8. Any subject who has received any of the following medications within the specified time-frame prior to the start of the study * Herbal preparations or drugs licensed for control of body weight or appetite (eg, orlistat, bupropion-naltrexone, phentermine-topiramate, phentermine, lorcaserin) within a year prior to the start of the study * Pioglitazone, SGLT2 or DPPIV inhibitors, GLP-1RA within the last 60 days at the time of screening 9. Severe allergy/hypersensitivity to any of the proposed study treatments, excipients, acetaminophen 10. Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight loss), a history of type 1 diabetes mellitus (T1DM) or diabetic ketoacidosis, or if the subject has been treated with daily SC insulin within 90 days prior to screening. 11. Significant inflammatory bowel disease or other severe disease or surgery affecting the upper GI tract (including weight-reducing surgery and procedures) which could affect the interpretation of safety and tolerability data. Prior history of bariatric surgery is not considered exclusion given the ample evidence of safety of use of GLP-1R therapy in this population. 12. Acute or chronic pancreatitis 13. Significant hepatic disease (except for metabolic dysfunction-associated steatohepatitis \[MASH\] or metabolic dysfunction-associated steatotic liver disease \[MASLD\]) without portal hypertension or cirrhosis) and/or subjects with any of the following results at screening: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN 14. Impaired renal function defined as estimated glomerular filtration rate (eGFR) \< 45 mL/minute/1.73m2 at screening (GFR estimated according to Modification of Diet in Renal Disease (MDRD) using MDRD Study Equation IDMS-traceable \[SI units\]) 15. Unstable angina pectoris, myocardial infarction, transient ischemic attack (TIA) or stroke within 3 months prior to screening, or subjects who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening 16. Severe congestive heart failure (New York Heart Association Class III or IV) 17. Basal calcitonin level \> 50 ng/L at screening or history/family history of medullary thyroid carcinoma or multiple endocrine neoplasia 18. History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell, squamous cell skin cancer, or in situ cervical cancer 19. History of HIV infection or other immune compromised disease; and history of organ transplantation 20. Substance dependence or history of alcohol abuse and/or excess alcohol intake 21. Patients on ketogenic diet
Conditions Major Depressive Disorder, Epilepsy
Phase NA
Enrollment 16
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to examine the feasibility and acceptability of an online group Neuro-behavioral Therapy (NBT) with text messaging intervention for Veterans with epilepsy and major depressive disorder (MDD).

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: Neurobehavioral therapy — Participants will receive an introduction session and 12 1-hour long online sessions once per week for a total of 12 weeks that are guided by the investigator who is trained in NBT.Participants will engage in tools to aid in assuming control over their seizures; contextualize their environment; identify moods, situations, and thoughts; train healthy communication and support seeking; understand central nervous system medications and seizures; conduct a functional behavioral analysis; learn relaxation techniques; examine external stressors and internal triggers; and prepare for life after the intervention. Participants will be asked to complete weekly homework, thought records, seizure logs that are found in their workbooks and to engage in journal entries.

Primary Outcomes

  • Enrollment rate (post intervention (14 weeks after baseline))
  • Retention rate (post intervention (14 weeks after baseline))
  • Session attendance rate (proportion of sessions attended) (post intervention (14 weeks after baseline))
  • Homework completion rate (proportion of homework assignments completed) (post intervention (14 weeks after baseline))
  • User satisfaction as assessed by The Participant Satisfaction Survey (post intervention (14 weeks after baseline))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-19
Completion: 2025-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 16 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center, Houston
Principal Investigators:
  • Melissa Fadipe, MSN, APRN, FNP-C (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center, Houston
Contact Information
Study Contact:
Melissa Fadipe, MSN, APRN, FNP-C
(713) 825-7237
Melissa.F.Fadipe@uth.tmc.edu
Jennifer Beauchamp
(713) 500-2114
Jennifer.E.Beauchamp@uth.tmc.edu
Melissa Fadipe, MSN, APRN, FNP-C
(713) 825-7237
Melissa.F.Fadipe@uth.tmc.edu
Michael E. DeBakey VA Medical Center
Interventions
  • Behavioral: Neurobehavioral therapy — Participants will receive an introduction session and 12 1-hour long online sessions once per week for a total of 12 weeks that are guided by the investigator who is trained in NBT.Participants will engage in tools to aid in assuming control over their seizures; contextualize their environment; identify moods, situations, and thoughts; train healthy communication and support seeking; understand central nervous system medications and seizures; conduct a functional behavioral analysis; learn relaxation techniques; examine external stressors and internal triggers; and prepare for life after the intervention. Participants will be asked to complete weekly homework, thought records, seizure logs that are found in their workbooks and to engage in journal entries.
Study Locations (2 sites)
Michael E. DeBakey VA Medical Center, Houston, Texas 77030 United States
The University of Texas health Science Center at Houston, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * English speaking veterans * has home internet access * has access to and familiarity in using a computer or tablet at least weekly * Asymptomatic patients with chronic conditions * has access to a mobile device with Short Message Service (SMS) text and picture capability * has an active clinical diagnosis of major depressive disorder based on the International Classification of Diseases, 10th version (ICD-10) * has an ICD-10 diagnosis of epilepsy with at least one seizure documented within the last five years Exclusion Criteria: * pregnancy * Veterans that have current suicidal ideation * have active psychosis; and have an ICD-10 diagnosis of psychogenic non-epileptic seizures or conversion disorder.
Conditions Depression
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to learn the extent to which client-therapist brain activity may synchronize during a psychosocial intervention for depression symptoms. The study will compare behavioral activation, a client-centered type of cognitive-behavioral therapy, to psychoeducation which delivers information on strategies to recover from depression symptoms. Participants will answer questions about their mental and physical health, attend one psychosocial intervention session receiving either Behavioral Activation or Psychoeducation with simultaneous brain activity measurement and complete follow up surveys two weeks and one month following the intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Psychoeducation — For the psychoeducation session, the focus is for the therapist to engage with the client regarding mental health broadly without a targeted effort to reinforce therapeutic alliance or to offer individualized guidance or techniques. The session will provide educational information on depression, depression symptoms and known causes, and strategies to reduce depression symptoms. The content will be delivered in a fashion to avoid individualization and psychotherapeutic exchange. The elements will focus on components of Cognitive Behavioral Therapy (CBT), differentiating between thoughts and feelings, common cognitive shortcuts, and the connection between behavior and emotion.
  • Behavioral: Behavioral Activation — Behavioral Activation (BA) is a psychotherapy treatment modality used for depression and focuses on replacing maladaptive coping mechanism that reinforce depressive symptoms with adaptive coping mechanisms to increase exposure to positive reinforcement. The treatment will consist of the following elements: Introduction to establish concept of positive reinforcement and build rapport, identification of client-centered values, individualized values-based activity planning and scheduling, and developing adaptive coping strategies for the future.

Primary Outcomes

  • Inter-brain phase synchronization in Alpha frequency band via Phase Locking Value (During the interventional session, approximately 60 minutes)
  • Inter-brain phase synchronization in Theta frequency band via Phase Locking Value (During the interventional session, approximately 60 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-11
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of North Carolina, Chapel Hill
Collaborators: Foundation of Hope, North Carolina
Principal Investigators:
  • Flavio Frohlich (PRINCIPAL_INVESTIGATOR) - Carolina Center for Neurostimulation
Contact Information
Study Contact:
Flavio Frohlich
(919) 966-4584
flavio_frohlich@med.unc.edu
Zachary Stewart
zachary_stewart@med.unc.edu
Flavio Frohlich, PhD
919-966-4584
flavio_frohlich@med.unc.edu
Carolina Center for Neurostimulation
Interventions
  • Behavioral: Psychoeducation — For the psychoeducation session, the focus is for the therapist to engage with the client regarding mental health broadly without a targeted effort to reinforce therapeutic alliance or to offer individualized guidance or techniques. The session will provide educational information on depression, depression symptoms and known causes, and strategies to reduce depression symptoms. The content will be delivered in a fashion to avoid individualization and psychotherapeutic exchange. The elements will focus on components of Cognitive Behavioral Therapy (CBT), differentiating between thoughts and feelings, common cognitive shortcuts, and the connection between behavior and emotion.
  • Behavioral: Behavioral Activation — Behavioral Activation (BA) is a psychotherapy treatment modality used for depression and focuses on replacing maladaptive coping mechanism that reinforce depressive symptoms with adaptive coping mechanisms to increase exposure to positive reinforcement. The treatment will consist of the following elements: Introduction to establish concept of positive reinforcement and build rapport, identification of client-centered values, individualized values-based activity planning and scheduling, and developing adaptive coping strategies for the future.
Study Locations (1 sites)
Carolina Center for Neurostimulation, Chapel Hill, North Carolina 27516 United States
Eligibility Criteria
Inclusion Criteria for participants/clients: * Between ages 18 and 30 * Full-time student status (undergraduate, graduate, and professional) * Experience mild to moderate depressive symptoms as determined by the Beck Depression Inventory (score: 14-28) * Capacity to understand study procedures (informed consent) * Ability to speak and understand English * Willingness to comply with study procedures Inclusion Criteria for therapists: * Ages 18 or older * Qualification to administer therapy (decided by the Principal Investigator) * Capacity to understand the study procedures (informed consent) * Speak and understand English * Willingness to comply with study procedures Exclusion Criteria for participants/clients: * Active, Current Suicidal ideation as determined by the Columbia-Suicide Severity Rating Scale (C-SSRS) in the past month * Past suicidal attempt (lifetime) * Recently initiated psychotherapy (past month) * Elevated psychosis risk based on self-report prodromal questionnaire - brief version (PQ-B) or self-reported diagnosis of psychotic disorder by mental health provider * Positive screen for autism spectrum disorder based on the self-report autism quotient (AQ-10) or self-reported diagnosis of autism spectrum disorder by mental health provider, * Daily intake of benzodiazepine of \>20 mg diazepam milligram equivalent * Inability to give informed, voluntary, written consent to participate * Inability to effectively communicate in English as determined by interaction with study personnel * Anything else that in the assessment of the study team is not conducive to the successful completion of the study requirements. There are no exclusion criteria for therapists
Conditions Breast Cancer, Radiotherapy Side Effect
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to identify potential genetic and other molecular biomarkers of response to radiation therapy in breast cancer that may help to personalize breast cancer radiation treatment in the future.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Adverse events of radiation therapy (Within 1 month after completion of radiotherapy)
  • Adverse events of radiation therapy (6 months after radiotherapy)
  • Adverse events of radiation therapy (2 years after radiotherapy)
  • Adverse events of radiation therapy (5 years after radiotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-11-01
Completion: 2029-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute of Oncology Ljubljana
Collaborators: University of Ljubljana, Faculty of Medicine, University Medical Centre Ljubljana
Principal Investigators:
  • Tanja Marinko, MD, PhD (PRINCIPAL_INVESTIGATOR) - Institute of Oncology Ljubljana
Contact Information
Study Contact:
Tanja Marinko, MD, PhD
0038615879505
tmarinko@onko-i.si
Tanja Marinko, MD, PhD
0038615879505
tmarinko@onko-i.si
Institute of Oncology Ljubljana
Tanja Marinko, MD, PhD
Institute of Oncology Ljubljana
Interventions
N/A
Study Locations (1 sites)
Institute of Oncology Ljubljana, Ljubljana, 1000 Slovenia
Eligibility Criteria
Inclusion Criteria: * Breast cancer patients with DCIS with an indication for adjuvant radiation therapy Exclusion Criteria: * Any specific systemic oncological therapy
Conditions Breast Cancer
Phase NA
Enrollment 148
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study focuses on preoperative treatment modalities for luminal-type locally advanced breast cancer. Based on modern precision radiotherapy technologies such as MRI-Linac, CyberKnife, and VMAT, it aims to compare the pCR rate, breast conserving surgery (BCS) rate, progression-free survival (PFS), and treatment-related side effects between preoperative neoadjuvant chemotherapy and preoperative neoadjuvant SBRT combined with chemotherapy in patients with this type of breast cancer. The goal is to provide new strategic options for the preoperative treatment of luminal-type locally advanced breast cancer.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Preoperative SBRT for the Primary Lesion of Breast Cancer — SBRT for Primary Lesion of Breast Cancer, Radiation Dose: Primary Lesion ≤3 cm, GTV 24Gy/3F; Primary Lesion \>3 cm, GTV 30Gy/5F.

Primary Outcomes

  • pCR (From enrollment to one month after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-18
Completion: 2027-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 148 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sichuan Cancer Hospital and Research Institute
Principal Investigators:
  • Qian Peng, Phd (PRINCIPAL_INVESTIGATOR) - Sichuan Cancer Hospital and Research Institute
  • Junjie Li, Phd (PRINCIPAL_INVESTIGATOR) - Sichuan Cancer Hospital and Research Institute
Contact Information
Study Contact:
Qian Peng, Phd
86-028-85420059
pengqian@scszlyy.org.cn
Rui Li, MD
86-028-85420590
lirui1@scszlyy.org.cn
Qian Peng, PhD
pengqian@scszlyy.org.cn
Sichuan Cancer Hospital
Interventions
  • Radiation: Preoperative SBRT for the Primary Lesion of Breast Cancer — SBRT for Primary Lesion of Breast Cancer, Radiation Dose: Primary Lesion ≤3 cm, GTV 24Gy/3F; Primary Lesion \>3 cm, GTV 30Gy/5F.
Study Locations (1 sites)
Sichuan Cancer Hospital, Chengdu, Sichuan 610041 China
Eligibility Criteria
Inclusion Criteria: 1. Pathologically confirmed invasive breast cancer ; 2. Breast MRI showing stages IIB to IIIC (2017 AJCC 8th edition staging); 3. Clinical staging confirmed by chest MRI and/or axillary ultrasound, as well as CT scans of the neck, abdomen, and pelvis, and bone scintigraphy, including T and N staging and assessment of distant metastasis; 4. Karnofsky performance score ≥80 or ECOG performance status of 0-1; 5. No history of allergies to doxorubicin, cyclophosphamide, paclitaxel/docetaxel; 6. No prior exposure to radiotherapy, chemotherapy, endocrine therapy, targeted therapy, or immunotherapy. Exclusion Criteria: 1. History of malignancy at other sites, excluding curable non-melanoma skin cancer and carcinoma in situ of the cervix; 2. Inability to complete MRI; 3. Inflammatory breast cancer; 4. Bilateral or multifocal primary tumors; 5. Active infection currently present; clinically evident heart disease; myocardial infarction or cerebrovascular accident within 6 months prior to enrollment.
Conditions Hypertension, Dyslipidemia
Phase PHASE3
Enrollment 162
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: JW0104+C2402 — For 8 weeks(PO (Per Oral), QD)
  • Drug: JW0104+C2403 — For 8 weeks(PO, QD)
  • Drug: C2402 — For 8 weeks(PO, QD)

Primary Outcomes

  • Change from baseline in msSBP (Systolic Blood Pressure) (week 8)
  • Percent change from baseline in LDL-C (Low-Density Lipoprotein Cholesterol) (week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-12-02
Completion: 2026-04
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 162 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: JW Pharmaceutical
Principal Investigators:
  • Minjung Kim (STUDY_CHAIR) - JW Pharmaceutical
Contact Information
Study Contact:
Minjung Kim
+82-2-840-6861
kmj@jwhealthcare.com
Dongryung Lee
+82-2-840-6982
dongryung.lee@jwhealthcare.com
Minjung Kim
+82-2-840-6861
kmj@jwhealthcare.com
Gangdong Sacred Heart Hospital
Interventions
  • Drug: JW0104+C2402 — For 8 weeks(PO (Per Oral), QD)
  • Drug: JW0104+C2403 — For 8 weeks(PO, QD)
  • Drug: C2402 — For 8 weeks(PO, QD)
Study Locations (1 sites)
Gangdong Sacred Heart Hospital, Seoul, 05355 South Korea
Eligibility Criteria
Inclusion Criteria: * Patients with hypertension and dyslipidemia Exclusion Criteria: * The subject not meet the specified msBP and LDL-C level
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Glucose monitoring is an important part of self-management for patients with diabetes. The results of glucose monitoring not only help to assess the degree of glucose metabolism disorders in patients, but also help physicians to make clinical decisions and guide patients in self-management. Despite extensive efforts and advances in diabetes management during hospitalization, glucose control after patients is discharged home remains a challenge. This trial aims to explore the effect of real-time continuous glucose monitoring (RT-CGM) system compared to self-monitoring of blood glucose (SMBG) group on glucose and self-efficacy of type 2 diabetes patients treated with insulin after discharge from the hospital.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: RT-CGM — This group of patients will wear RT-CGM for blood glucose monitoring for three months.
  • Device: SMBG — This group of patients will use a a fingertip glucose meter for blood glucose monitoring for three months, and the monitoring frequency was not less than 4 times per week.

Primary Outcomes

  • Time in range (3.9~10.0mmol/L, %) (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-25
Completion: 2027-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai 6th People's Hospital
Principal Investigators:
  • Jian Zhou, Dr. (PRINCIPAL_INVESTIGATOR) - Shanghai 6th People's Hospital
Contact Information
Study Contact:
Shiyun Wang, Dr.
+86 21 2405 8570
rhyme2008@alumni.sjtu.edu.cn
Shiyun Wang, PhD
rhyme2008@alumni.sjtu.edu.cn
Shanghai 6th People's Hospital
Interventions
  • Device: RT-CGM — This group of patients will wear RT-CGM for blood glucose monitoring for three months.
  • Device: SMBG — This group of patients will use a a fingertip glucose meter for blood glucose monitoring for three months, and the monitoring frequency was not less than 4 times per week.
Study Locations (1 sites)
Shanghai 6th People's Hospital, Shanghai, Shanghai Municipality 200233 China
Eligibility Criteria
Inclusion Criteria: 1. 18 years old ≤ age ≤ 80 years old. 2. Type 2 diabetes admitted to Department of Endocrinology and Metabolism. 3. 8% ≤ HbA1c ≤ 12% in the last 1 month. 4. Insulin therapy within 1 month of planned discharge from hospital. 5. Frequency of self-monitoring of blood glucose \<4 times per week and no use of real-time continuous glucose monitoring system in the 3 months prior to hospitalisation. 6. Willing and able to provide written informed consent and comply with the requirements of this study. Exclusion Criteria: 1. Oral steroid hormone therapy. 2. Patients with acute complications of diabetes (including Diabetic ketoacidosis, hyperglycemia and hyperosmolality, Lactic acidosis) 3. Patients with severe liver disease (alanine aminotransferase or glutamine aminotransferase exceeding more than three times the upper limit of normal). 4. Patients with severe kidney injury or end-stage renal disease (eGFR \< 30 mL/min/1.73 m2). 5. Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area. 6. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study. 7. Pregnant, breastfeeding, women of childbearing age who are unwilling to use contraception during the study period.

PIK3CA Mutational Status Assessment

NCT06706570
Recruiting
Conditions Breast Cancer Metastatic
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Evaluation of PIK3CA mutational status: a route towards a tailored diagnostic approach.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Evaluation of PIK3CA mutational status: a path towards a "tailored" diagnostic approach. (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-06
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: European Institute of Oncology
Principal Investigators:
  • Nicola Fusco, MD (PRINCIPAL_INVESTIGATOR) - Istituto Europeo di Oncologia
Contact Information
Study Contact:
Nicola Fusco, MD
00390294372079
nicola.fusco@ieo.it
francesca lombardi, biologist
00390257489425
francesca.lombardi@ieo.it
Nicola Fusco, MD
00390294372079
nicola.fusco@ieo.it
European Institute of Oncology
Interventions
N/A
Study Locations (1 sites)
European Institute of Oncology, Milan, MI 20141 Italy
Eligibility Criteria
Inclusion Criteria: * Participant has a histologically and/or cytologically confirmed diagnosis of ER+ and/or PgR+ breast cancer by local laboratory. * Participant has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (Fluorescent in situ hybridization (FISH), Chromogenic in situ hybridization (CISH), or Silver-enhanced in situ hybridization (SISH)) test is required by local laboratory testing. * Participants should be at advanced or metastatic setting prior to treatment. * Written informed consent must be signed and dated by the patient and the investigator prior to inclusion. * Patients must be accessible for follow-up. Exclusion Criteria: • patients already treated with different treatments like chemotherapy, hormone therapy etc
Conditions Breast Cancer Surgery, ESPB
Phase Not Applicable
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to to evaluate the changes in cold sensitivity and the onset of sensory block after performing a thoracic ESP block. It reflects the time it takes for the local anaesthetic to spread into the paravertebral space leading to changes in cold sensitivity in the chest. The study population are patients undergoing simple quadrantectomy or partial resection with or without sentinel lymphnode removal, in the operating rooms of Santa Maria Goretti Hospital in Latina. This study is observational because it simply describes and records the effects of a procedure (the ESP block) on treated patients during a period of observation. Before surgery, unilateral thoracic ESP block (T4 level) with a sterile, ultrasound-guided technique will be performed. A timer will be started to mark the time for subsequent evaluations. At 1,3,5 and after every 5 minutes following the block up to 40 minutes or until induction of general anaesthesia, the cold sensitivity of the chest will be explored.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Procedure: ESP block — The ESPB will be performed at the T4 level, monolaterally (according to the surgical side), with 30ml volume of 0.5% Ropivacaine injected with a 20-gauge, 50-mm-long needle. The technique used is the standard ultrasound-guided, sterile procedure. Soon after performing the block, a timer will be started to mark the time for subsequent evaluations. At 1,3,5 and after every 5 minutes following the block until 40 minutes or until general anaesthesia is induced, the cold sensitivity of the chest will be explored.

Primary Outcomes

  • The onset of sensory block after thoracic ESP block after one minute (One minute after ESPB is performed)
  • The onset of sensory block after thoracic ESP block after three minutes (3 minutes after ESPB is performed)
  • The onset of sensory block after thoracic ESP block after five minutes (5 minutes after ESPB is performed)
  • The onset of sensory block after thoracic ESP block after 10 minutes (10 minutes after ESPB is performed)
  • The onset of sensory block after thoracic ESP block after 15 minutes (15 minutes after ESPB is performed)
  • The onset of sensory block after thoracic ESP block after 20 minutes (20 minutes after ESPB is performed)
  • The onset of sensory block after thoracic ESP block after 25 minutes (25 minutes after ESPB is performed)
  • The onset of sensory block after thoracic ESP block after 30 minutes (30 minutes after ESPB is performed)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-11-07
Completion: 2025-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ospedale Santa Maria Goretti
Contact Information
Study Contact:
Irene Lupelli, MD
+39 3497772231
irene.lupelli@gmail.com
Alessandro De Cassai, MD
+39 3204169392
alessandro.decassai@gmail.com
Irene Lupelli, MD
+39 3497772231
irene.lupelli@gmail.com
Ospedale Santa Maria Goretti, Via Lucia Scaravelli
Interventions
  • Procedure: ESP block — The ESPB will be performed at the T4 level, monolaterally (according to the surgical side), with 30ml volume of 0.5% Ropivacaine injected with a 20-gauge, 50-mm-long needle. The technique used is the standard ultrasound-guided, sterile procedure. Soon after performing the block, a timer will be started to mark the time for subsequent evaluations. At 1,3,5 and after every 5 minutes following the block until 40 minutes or until general anaesthesia is induced, the cold sensitivity of the chest will be explored.
Study Locations (1 sites)
Ospedale Santa Maria Goretti, Via Lucia Scaravelli, Latina, Italy 04100 Italy
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years. * ASA score I-II-III. * Schedule of breast surgery * Schedule of ESPB * Consent to the study Exclusion Criteria: * Allergy to local anaesthetics * Cardiopathies, nephropathies, hepatopathies, central or peripheral neuropathies uncompensated * Infection at the injection site * Uncooperative patient * BMI \< 20, \> 40 * Difficulty in visualising target structures or the LA spread (failure of technique) * Pregnancy status
Conditions Breast Cancer, Radiotherapy Side Effect
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Partial breast irradiation is currently a hot topic in clinical research, but the appropriate population and appropriate irradiation The technology and dose fractionation mode are still inconclusive. Foreign studies have mostly selected patients with low risk of recurrence. Breast-conserving surgeries for early-stage breast cancer are increasing year by year in China. It is necessary to conduct prospective clinical studies to explore the Chinese population suitable for partial breast irradiation and the appropriate radiotherapy dose fractionation model. A preliminary study in our center has compared the safety and efficacy of a 2-week schedule of partial breast irradiation (40Gy/10f) and a 3-week schedule of whole-breast radiotherapy (43.5Gy/15f) in patients with early-stage low-risk breast cancer after breast-conserving surgery. , preliminary results show that the 2-week partial breast irradiation regimen is safe and effective. This study plans to continue to select low-risk breast-conserving patients, use extracorporeal intensity-modulated radiotherapy technology, refer to the radiotherapy dose fractionation model of the FAST-Forward study, and give partial breast irradiation 5.2 Gy/f/d, a total of 5 times, with a total dose of 26Gy, to further shorten the time The radiotherapy time is 1 week, and the acute and late adverse reactions of radiotherapy and the local control of the tumor are prospectively observed. Provide evidence for conducting a national multi-center phase III clinical randomized study.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Partial Breast Irradiation — 26Gy/5.2Gy/5f

Primary Outcomes

  • Incidence of acute adverse reactions (up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-04-22
Completion: 2027-09
Eligibility
Age: 45 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Guangyi Sun
086-18811100731
sungy@cicams.ac.cn
Guangyi Sun
086-18811100731
sungy@cicams.ac.cn
Cancer Hospital ,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Shulian Wang, MD
Cancer Hospital ,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Interventions
  • Radiation: Partial Breast Irradiation — 26Gy/5.2Gy/5f
Study Locations (1 sites)
Cancer Hospital ,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria: 1. ≥45 years old, \<75 years old women 2. Life expectancy \>5 years 3. Start radiotherapy within 12 weeks after breast-conserving surgery (or within 8 weeks from the end of chemotherapy) 4. Invasive ductal carcinoma grade 1-2, or mucinous carcinoma, papillary carcinoma, canalicular carcinoma, medullary carcinoma; primary tumor ≤3.0cm; both pN0 (axillary dissection or sentinel lymph node biopsy) 5. Low-risk DCIS: tumor ≤2.5cm, low to medium grade; axillary surgery is not required or pN0 6. Single focus (with MRI diagnosis) 7. Vascular tumor thrombus negative 8. ER and/or PR positivity (defined as strong positivity in \>1% of tumor cell nuclei) 9. Negative pathological margin≥2mm 10. Place metal markers on the tumor bed 11. Sign the informed consent form Exclusion Criteria: 1. Multiple primary tumors 2. Invasive ductal carcinoma grade 3 3. Invasive micropapillary carcinoma 4. Lobular carcinoma in situ 5. Invasive lobular carcinoma 6. Simple nipple paget's disease 7. Oncoplastic surgery 8. Neoadjuvant chemotherapy or neoadjuvant endocrine therapy 9. Previous or simultaneous contralateral breast cancer 10. History of ipsilateral chest wall radiotherapy 11. Have active collagen vascular disease
Conditions Depression, Suicidality, Sleep
Phase NA
Enrollment 420
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multi-site randomized control trial involving people age 55+ years who have current depression symptoms plus another suicide risk indicator (either current suicidal ideation or a past history of attempt). Our goal is evaluate which of two different approaches works best to improve things like trouble sleeping, bad moods, and any suicidality. Participants will complete diagnostic interviews, self-report scales, and wear an actigraphy device for the 8 weeks starting at the baseline visit.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Other: Treatment As Usual — In this trial, all participants will have depression symptoms and will be receiving TAU from their own doctors.
  • Behavioral: Active Condition — Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
  • Behavioral: Active Comparator — Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.

Primary Outcomes

  • Depression Symptom Response (six months post-treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-20
Completion: 2030-08
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: false
Enrollment: 420 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: Emory University, University of California, Berkeley, University of California, Los Angeles, Augusta University, National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Principal Investigators:
  • Stephen F Smagula, Ph.D (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Sara Sellars, M.A
412-246-5963
alberts3@upmc.edu
Stephen Smagula, Ph.D
412-246-6674
smagulasf@upmc.edu
Michael Irwin, PhD
310-825-8281
mirwin1@ucla.edu
The Regents of the University of California, Los Angeles
Interventions
  • Other: Treatment As Usual — In this trial, all participants will have depression symptoms and will be receiving TAU from their own doctors.
  • Behavioral: Active Condition — Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
  • Behavioral: Active Comparator — Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
Study Locations (3 sites)
The Regents of the University of California, Los Angeles, Los Angeles, California 90095 United States
Augusta University, Augusta, Georgia 30912 United States
University of Pittsburgh, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: * Age 55 Years and older * Patient Health Questionnaire -9 score of 10 or higher * Past month Scale for Suicide Ideation score of 3 or higher OR any history of suicide attempt * PROMIS Sleep Disturbance or impairment scale t-scores of 55 or higher * Pharmacotherapy for depression meeting minimum adequate dose level as defined by FDA approval documents for at least 4 weeks. Exclusion Criteria: * Active suicide planning with intent or clinical judgement that suicide risk is too high for outpatient treatment OR being currently treated at an inpatient unit. * Bipolar disorder * Psychotic disorder * Borderline personality disorder. * Active Cognitive/Behavioral Therapy (e.g., CBT-I), current or upcoming esketamine (ketamine) treatment, or active phase of ECT/TMS treatment course. * Illness with life expectancy of less than 1 year or plans to leave the study area * Incapacity to consent/dementia diagnosis * Active substance use disorder of at least moderate severity * Active night-shift work * Any physical, mental, or neurological condition that would make participation in the study, including either treatment arm, unsafe or infeasible.
Conditions Bipolar II Disorder, Depression, Bipolar...
Phase PHASE2
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Psilocybin — Two sequential administrations of 25 mg psilocybin, 4 weeks apart.
  • Behavioral: Therapeutic Support — Five preparatory in-person psychotherapy sessions will be offered before the first administration session during weeks 1, 2, 3, 4, and 5. The optional second administration session will be preceded by a shorter 60 min preparatory session the day before. Each administration session will be followed by 3 integration sessions and will adopt a Mindfulness-based CBT approach (M-CBT), in which a therapist will help the participant to process their experience and how to translate this into actual changes in everyday life. If participants prefer more psychological support after the second administration session, they will be offered additional, optional therapy sessions for the duration of the trial regardless if they opted for a second administration session or not.

Primary Outcomes

  • Feasibility as Assessed by Number of Participants who Complete the Trial (Overall Retention) (from baseline to 3 weeks after first administration session)
  • Feasibility as Assessed by Number of Therapy Sessions Attended (from baseline to 3 weeks after first administration session)
  • Feasibility as Assessed by Number of Assessments Completed (from baseline to 3 weeks after first administration session)
  • Acceptability of Two Dosing Sessions as Assessed by Number of Participants who Choose to Participate in a Second Administration Session (11 weeks after first administration session)
  • Acceptability as Assessed by Number of Therapy Sessions Attended (from baseline to 11 weeks after first administration session)
  • Acceptability as Assessed by Number of Assessments Completed (from baseline to 11 weeks after first administration session)
  • Score on the Thwarted Belongingness (TB) Items of the Interpersonal Needs Questionnaire (INQ-15) (baseline, 3 weeks after first administration session)
  • Score on the Perceived Burdensomeness (PB) Items of the Interpersonal Needs Questionnaire (INQ-15) (baseline, 3 weeks after first administration session)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-07
Completion: 2027-08
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center, Houston
Collaborators: Anne and Don Fizer Foundation
Principal Investigators:
  • Thomas Meyer, PhD (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center, Houston
Contact Information
Study Contact:
Thomas Meyer, PhD
713-486-2643
thomas.d.meyer@uth.tmc.edu
Griffin McClain
7134862643
Griffin.McClain@uth.tmc.edu
Thomas Meyer, PhD
713-486-2643
thomas.d.meyer@uth.tmc.edu
The University of Texas Health Science Center at Houston
Interventions
  • Drug: Psilocybin — Two sequential administrations of 25 mg psilocybin, 4 weeks apart.
  • Behavioral: Therapeutic Support — Five preparatory in-person psychotherapy sessions will be offered before the first administration session during weeks 1, 2, 3, 4, and 5. The optional second administration session will be preceded by a shorter 60 min preparatory session the day before. Each administration session will be followed by 3 integration sessions and will adopt a Mindfulness-based CBT approach (M-CBT), in which a therapist will help the participant to process their experience and how to translate this into actual changes in everyday life. If participants prefer more psychological support after the second administration session, they will be offered additional, optional therapy sessions for the duration of the trial regardless if they opted for a second administration session or not.
Study Locations (1 sites)
The University of Texas Health Science Center at Houston, Houston, Texas 77006 United States
Eligibility Criteria
Inclusion Criteria: * Must have completed written informed consent * Must be at 25 years of age or older at screening (but below age of 70) * Confirmed Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of BD-II using clinical records and Diagnostic Interview for Anxiety, Mood, and Obsessive-compulsive disorder (OCD) and Related Neuropsychiatric Disorders (DIAMOND) * Must meet criteria for suicidality according to the INQ cutoff scores: A score of at least 12 on the Perceived Burden (PB) subscale and at least a score of 36 on the Thwarted Belongingness (TB) subscale indicating substantial risk for passive suicidal ideation * Must meet criteria for depression according to the MADRS cutoff scores: A score of 7-34 indicating mild to moderate depression * Must pass medical examination (physical exam, personal/family medical history, including consultation with current medical provider, ECG, about 4 tablespoons blood draw, psychiatric/psychological assessments, urine drug test) * Willingness to taper down mood stabilizers and other relevant medications (including but not limited to: antidepressants, antipsychotics, lithium, benzodiazepines, Monoamine oxidase inhibitors (MAOIs), Selective serotonin reuptake inhibitors (SSRIs), Serotonin and norepinephrine reuptake inhibitors (SNRIs), A serotonin-norepinephrine-dopamine reuptake inhibitors (SNDRIs), Tricyclic antidepressants (TCAs), stimulants, cannabis, and other medications, supplements or therapeutics that affect serotonergic function) for the duration of the study before and during administration days (starting 5 weeks before administration), and be off medication for at least 2 weeks prior to administration * Willingness to stop allowed medication at least 24 h prior to administration of psilocybin as advised by study physician (e.g., benzodiazepines) * Ability to complete all protocol required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits Exclusion Criteria: * Participants who do not read/speak English * Active suicidal ideation with at least some intent and/or plan (i.e., a current score of 4 or 5 on the C-SSRS) * History of medically significant suicide attempt in the last 6 months * Current or past history of Bipolar I disorder, psychotic symptoms or psychotic disorder, (including but not limited to schizophrenia, delusional disorder, schizoaffective disorder) clinically relevant personality disorder (such as borderline, antisocial, narcissistic or paranoid personality disorder), or any serious psychiatric comorbidity considered negatively impacting participation or safety (e.g., PTSD or severe substance use or alcohol disorder) assessed by medical history and/or a structured clinical interview * Have a first or second degree relative with Bipolar I disorder or a psychotic disorder * Currently experiencing a hypomanic or mixed-symptom episode * Have a psychiatric or other condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin * Any indication of a Personality Disorder (PD) such as but not limited to Borderline, Narcissistic, Antisocial, Paranoid, or Schizotypal PD based on Structured Clinical Interview for DSM-5 for PD and/or clinical judgment